Tara DeSilva bought $1,305 of ZSQR
director at Coeptis Therapeutics Holdings, Inc.. 2,266 shares at an average of $0.58, traded Jan 12, 2024, filed Jan 16, 2024.
Score components
- +15RoleDirector
- 0Trade size$1k at market
- +3Relative to holdingsHoldings up 8%
- +18Price context2% above the 52-week low; 72% below the 52-week high
- +15Cluster6 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001683168-24-000319, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 12, 2024 | POpen-market purchase Common Stock | +466 | $0.56 | $261 | 30,466 | Jan 16, 2024 |
| Jan 12, 2024 | POpen-market purchase Common Stock | +1,800 | $0.58 | $1,044 | 32,266 | Jan 16, 2024 |
Related signals
Other insiders at Coeptis Therapeutics Holdings, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 39Weak | ZSQRbuy Coeptis Therapeutics Holdings, Inc. | Christopher Ryan Schadel Chief Marketing Officer | $3,920 1,000 shares | +41% | |
| 41Moderate | ZSQRbuy Coeptis Therapeutics Holdings, Inc. | Christopher Ryan Schadel Chief Marketing Officer | $3,920 1,000 shares | - | |
| 61Notable | Coeptis Therapeutics Holdings, Inc. | Brian Cogley Chief Financial Officer | $3,350 5,000 shares | +20% | |
| 54Moderate | Coeptis Therapeutics Holdings, Inc. | Christopher P. Cochran director | $5,390 7,000 shares | +23% | |
| 53Moderate | Coeptis Therapeutics Holdings, Inc. | David Mehalick CEO and President | $17k 25,054 shares | +1% | |
| 43Moderate | Coeptis Therapeutics Holdings, Inc. | Gene Salkind director | $8,004 11,600 shares | +4% | |
| 48Moderate | Coeptis Therapeutics Holdings, Inc. | Daniel Alexander Yerace VP of Operations | $7,487 10,850 shares | +1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.